| Articolul precedent |
| Articolul urmator |
 |
 218 0 |
 SM ISO690:2012PĂLĂRIE, Natalia, PALII, Natalia. Transscleral cyclophotocoagulation in refractory glaucoma in eyes with good vision. In: Black Sea Ophthalmological Society Congress, Ed. 19, 24-26 septembrie 2021, Chisinau. Chişinău: CEP UPS „I.Creangă”, 2021, Ediția 19, p. 45. |
| EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
| Black Sea Ophthalmological Society Congress Ediția 19, 2021 |
||||||
|
Congresul "Black Sea Ophthalmological Society Congress, " 19, Chisinau, Moldova, 24-26 septembrie 2021 | ||||||
|
||||||
| Pag. 45-45 | ||||||
|
||||||
 Descarcă PDF |
||||||
| Rezumat | ||||||
Introduction: Transscleral diode laser cyclophotocoagulation (TSCPC) is a well-known method of treatment for advanced and refractory glaucoma, but it is not used routinely in eyes with good vision. Purpose: This prospective study was conducted to evaluate the efficacy and safety of TSCPC in eyes with refractory glaucoma and best corrected visual acuity (BCVA) better than 0,3. Methods: This prospective interventional case series included 62 eyes with refractory glaucoma of 42 consecutive patients treated with TSCPC. BCVA varied from 0,3 to 0,5; mean IOP prior to procedure was 40 ± 12 mm Hg. The 810 nm infrared diode laser was delivered at 1200 mW for 4 seconds over 270°-300°. The power was increased in 150 mW increments until an audible “pop” is heard, followed by a decrease of 150 mW to complete the treatment. A reduction in the number of antiglaucoma drops (AGD) and an IOP of 11-21 mm Hg at the last follow-up visit was defined as success. Patients were followed at baseline, week 1, month 1, 3, 6 and 12 after the TSCPC. Results: A mean of 1.3 treatments were given per eye, with 20 eyes (32%) requiring retreatment at the 1st month of follow up. Mean IOP decreased to 26.5 ± 5.0 mm Hg at 1 week, 20.0 ± 5.3 mm Hg at 1 month, 19.7 ± 3.4 mm Hg, 18.2 ± 2.7 mm Hg at 6 months. The overall success rate was 86%. AGD were reduced from 2.0 ± 1.0 at baseline to 1.1 ± 1.2 at 1 month, to 1.7 ± 1.0 at 3 months and to 2.2 ± 1.2 at 6 month follow-up. No patient had hypotony. TSCPC procedure failed in 9 patients with neovascular refractory glaucoma. Conclusions: 1. This study suggests a role of TSCPC as an effective, safe and rapid method of treatment in patients with refractory glaucoma with good vision over a 12-month period. 2. IOP becomes stably reduced only by the 3rd month after the TSCPC. 3. Studies with longer follow-up and larger sample size are needed to evaluate a long-term efficacy of TSCPC procedure. |
||||||
|
Dublin Core Export
<?xml version='1.0' encoding='utf-8'?> <oai_dc:dc xmlns:dc='http://purl.org/dc/elements/1.1/' xmlns:oai_dc='http://www.openarchives.org/OAI/2.0/oai_dc/' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' xsi:schemaLocation='http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd'> <dc:creator>Pălărie, N.L.</dc:creator> <dc:creator>Palii, N.</dc:creator> <dc:date>2021</dc:date> <dc:description xml:lang='en'><p>Introduction: Transscleral diode laser cyclophotocoagulation (TSCPC) is a well-known method of treatment for advanced and refractory glaucoma, but it is not used routinely in eyes with good vision. Purpose: This prospective study was conducted to evaluate the efficacy and safety of TSCPC in eyes with refractory glaucoma and best corrected visual acuity (BCVA) better than 0,3. Methods: This prospective interventional case series included 62 eyes with refractory glaucoma of 42 consecutive patients treated with TSCPC. BCVA varied from 0,3 to 0,5; mean IOP prior to procedure was 40 ± 12 mm Hg. The 810 nm infrared diode laser was delivered at 1200 mW for 4 seconds over 270°-300°. The power was increased in 150 mW increments until an audible “pop” is heard, followed by a decrease of 150 mW to complete the treatment. A reduction in the number of antiglaucoma drops (AGD) and an IOP of 11-21 mm Hg at the last follow-up visit was defined as success. Patients were followed at baseline, week 1, month 1, 3, 6 and 12 after the TSCPC. Results: A mean of 1.3 treatments were given per eye, with 20 eyes (32%) requiring retreatment at the 1st month of follow up. Mean IOP decreased to 26.5 ± 5.0 mm Hg at 1 week, 20.0 ± 5.3 mm Hg at 1 month, 19.7 ± 3.4 mm Hg, 18.2 ± 2.7 mm Hg at 6 months. The overall success rate was 86%. AGD were reduced from 2.0 ± 1.0 at baseline to 1.1 ± 1.2 at 1 month, to 1.7 ± 1.0 at 3 months and to 2.2 ± 1.2 at 6 month follow-up. No patient had hypotony. TSCPC procedure failed in 9 patients with neovascular refractory glaucoma. Conclusions: 1. This study suggests a role of TSCPC as an effective, safe and rapid method of treatment in patients with refractory glaucoma with good vision over a 12-month period. 2. IOP becomes stably reduced only by the 3rd month after the TSCPC. 3. Studies with longer follow-up and larger sample size are needed to evaluate a long-term efficacy of TSCPC procedure.</p></dc:description> <dc:source>Black Sea Ophthalmological Society Congress (Ediția 19) 45-45</dc:source> <dc:title>Transscleral cyclophotocoagulation in refractory glaucoma in eyes with good vision</dc:title> <dc:type>info:eu-repo/semantics/article</dc:type> </oai_dc:dc>
|
|
|
